<?xml version="1.0" encoding="utf-8"?>
<export-example>
  <doc>
    <id>1820</id>
    <completedYear>2021</completedYear>
    <publishedYear/>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst>160</pageFirst>
    <pageLast>165</pageLast>
    <pageNumber/>
    <edition/>
    <issue>2</issue>
    <volume>48</volume>
    <type>article</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>--</completedDate>
    <publishedDate>2021-12-07</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">Rare SARS-CoV-2 antibody development in cancer patients</title>
    <abstract language="eng">SARS-CoV-2 antibody development and immunity will be crucial for the further course of the pandemic. Until now, it has been assumed that patients who are infected with SARS-CoV-2 will develop antibodies as has been the case with other coronaviruses, like MERS-CoV and SARS-CoV. In the present study, we analyzed the development of antibodies in 77 patients with an oncologic diagnosis 26 days after positive RT-qPCR testing for SARS-CoV2. RT-qPCR and anti-SARS-CoV2-antibody methods from BGI (MGIEasy Magnetic Beads Virus DNA/RNA Extraction Kit) and Roche (Elecsys Anti-SARS-CoV-2 immunoassay) were used, respectively, according to the manufacturers’ specifications. Surprisingly, antibody development was detected in only 6 of 77 individuals with a confirmed history of COVID-19. Despite multiple testing, the remaining patients did not show measurable antibody concentrations in subsequent tests. These results undermine the previous hypothesis that SARS-CoV2 infections are regularly associated with antibody development and cast doubt on the provided immunity to COVID-19. Understanding the adaptive and humoral response to SARS-CoV2 will play a key role in vaccine development and gaining further knowledge on the pathogenesis.</abstract>
    <parentTitle language="eng">Seminars in Oncology</parentTitle>
    <identifier type="url">https://doi.org/10.1053/j.seminoncol.2020.12.003</identifier>
    <enrichment key="PeerReviewed">Ja</enrichment>
    <enrichment key="opus.source">publish</enrichment>
    <enrichment key="opus.doi.autoCreate">false</enrichment>
    <enrichment key="opus.urn.autoCreate">true</enrichment>
    <enrichment key="review.accepted_by">2</enrichment>
    <author>Louisa Hempel</author>
    <author>Jakob Molnar</author>
    <author>Sebastian Robert</author>
    <author>Julia Veloso</author>
    <author>Zeljka Trepotec</author>
    <author>Sofie Englisch</author>
    <author>Philip Weinzierl</author>
    <author>Cordula Schick</author>
    <author>Valeria Milani</author>
    <author>Katrin Schweneker</author>
    <author>Bastian Fleischmann</author>
    <author>Josef Scheiber</author>
    <author>Beate Gandorfer</author>
    <author>Axel Kleespies</author>
    <author>Dirk Hempel</author>
    <author>Kristina Riedmann</author>
    <author>Armin Piehler</author>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>SARS-CoV2 antibody development</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>COVID-19</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Cancer</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Immunity</value>
    </subject>
    <thesisPublisher>Technische Hochschule Rosenheim</thesisPublisher>
  </doc>
</export-example>
